Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    MK-1084

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Breakthrough Designation to Calderasib in KRAS NSCLC
    FDA Grants Breakthrough Designation to Calderasib in KRAS NSCLC

    29 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260529095946/en/FDA-Grants-Breakthrough-Therapy-Designation-for-Calderasib-MK-1084-an-Investigational-KRAS-G12C-Inhibitor-for-Certain-Patients-with-Newly-Diagnosed-Metastatic-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer-NSCLC

    BUSINESSWIRE
    29 May 2026
    Share Share
    Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC
    Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC

    11 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/merck-initiates-phase-3-trial-of-calderasib-with-keytruda-qlex-for-nsclc-18842

    INDPHARMAPOST
    11 Jan 2026
    Share Share
    Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX
    Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/merck-initiates-phase-3-kandlelit-007-trial-evaluating-calderasib-mk-1084-an-investigational-oral

    PHARMIWEB
    07 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.